- Home
- STSS vs PCSA Comparison
STSS vs PCSA Comparison
Compare STSS & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- PCSA
- Stock Information
- Founded
- STSS 2017
- PCSA 2011
- Country
- STSS United States
- PCSA United States
- Employees
- STSS N/A
- PCSA N/A
- Industry
- STSS Medical/Dental Instruments
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- STSS Health Care
- PCSA Health Care
- Exchange
- STSS Nasdaq
- PCSA Nasdaq
- Market Cap
- STSS 5.1M
- PCSA 4.3M
- IPO Year
- STSS 2022
- PCSA N/A
- Fundamental
- Price
- STSS $3.47
- PCSA $0.86
- Analyst Decision
- STSS
- PCSA Buy
- Analyst Count
- STSS 0
- PCSA 3
- Target Price
- STSS N/A
- PCSA $5.00
- AVG Volume (30 Days)
- STSS 63.4K
- PCSA 26.8K
- Earning Date
- STSS 11-14-2024
- PCSA 10-30-2024
- Dividend Yield
- STSS N/A
- PCSA N/A
- EPS Growth
- STSS N/A
- PCSA N/A
- EPS
- STSS N/A
- PCSA N/A
- Revenue
- STSS N/A
- PCSA N/A
- Revenue This Year
- STSS N/A
- PCSA N/A
- Revenue Next Year
- STSS N/A
- PCSA N/A
- P/E Ratio
- STSS N/A
- PCSA N/A
- Revenue Growth
- STSS N/A
- PCSA N/A
- 52 Week Low
- STSS $2.34
- PCSA $0.85
- 52 Week High
- STSS $18.15
- PCSA $17.40
- Technical
- Relative Strength Index (RSI)
- STSS 60.04
- PCSA 21.42
- Support Level
- STSS $2.54
- PCSA $0.85
- Resistance Level
- STSS $2.99
- PCSA $1.06
- Average True Range (ATR)
- STSS 0.33
- PCSA 0.08
- MACD
- STSS 0.12
- PCSA -0.02
- Stochastic Oscillator
- STSS 81.58
- PCSA 2.89
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).